Bryan Irving

Bryan Irving

Company: Amunix Pharmaceuticals Inc. – Sanofi

Job title: Chief Scientific Officer


Panel Discussion: Assessing Past Progress Successes with Various Targets 4:30 pm

HER2, PSMA, EPCAM, and CEA antigens present therapeutic opportunity: which of these presents as the most realistic option? Assess the cleanness of these antigen targets Highlight key strategies that can be leveraged to identify the cleanest targetsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.